Search 

Technology allows for a large quantity of active ingredient to be stored in a polymer matrix for a constant and slow targeted release. The active polymer is either embedded onto textile supports or on self adhesive multi layer long lasting patches or in particles in suspension in a solution. Products include pain relief devices (active textiles or patches), slimming devices, active foot care, mosquito control devices,...

We are able to have products lasting much longer because we can insert a large amount of actives in the device and we control the release kinetic. For instance, istead of having a 8 hour pain relief patch, we can obtain a reusable, washable patch equivalent lasting several weeks.

Rheumatology/ Orthopedics / Dermatology / Slimming / Parasite control

Long lasting active release / Constant release / Targeted area

Aderly Invest in Lyon is the economic development agency of Lyon - France

Industry sectors

•  it offers an attractive user friendly meal logging experience, avoiding manual search in a database for most of the foods: the scanning user experience takes up to 10 times less clicks to log a food than a manual self declarative input method /

• spectrometry makes possible accurate analysis of homogeneous food and beverage, taking into account specific cooking and additive ingredient

• the food database and its models will respond accurately on any homogeneous food, even on home made dishes and beverages that do not have a nutritional label /

• DietSensor gives a lot of feedback on food quality and quantity while logging food, making possible immediate behavior changes before eating

We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its nadditional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will nter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP.

AZP2006 is developed for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Progressive Supranuclear Palsy.

Alzheimer's disease, Progressive supranuclear palsy, Frontotemporal dementia, Parkinson's disease

Innovative mode of action/ first-in-class candidate drug/ clinical phase / Orphan status

Hands-free, mobile audio-video connection on smart glasses through a HIPAA exchange platform allowing the physician to communicate with the patient and nurse, permitting synchronous tele-consultations. Doctors can take pictures remotely, select areas within the photo to highlight, comment on and transfer to the nurse and patient file.

-TELEMEDICINE: AMA's solution brings healthcare expertise to patients, eliminating geographical constraints and improving quality care and patient comfort. - FINANCIAL challenges: reduces transport, hospitalisation costs and time consumption. - EMERGENCY: fast intervention, doubt removal, orientation to best-fitting hospital - E-LEARNING and mentoring: Live and personalised advice and guidance during training/interventions

Emergency 1 / Ambulances 2 / Nursing homes 3 / E-training 4

Mobility 1 / Hands-free 2 / Videoconferencing (audio - video exchanges) 3 / Efficient (cost and time saving) 4

Contacts:

• Jean-François DENIS, VP Sales
• Anne-Fleur ANDRLE, Business Development US

AMABIOTICS analyse metabolic interplays between humans and its microbial associated communities. AMABIOTICS discovered novel actions of natural chemical compounds provided by the microbiome that the host cannot synthesize by itself. Our pipeline of products candidates is led by AMA-101 as a potential first-in-class therapy for Parkinson disease.

We address the major issue of preventing mitochondrial dysfunction

1 - Neurodegenerative disease / 2 - Obesity / 3 - Tissue regeneration

Original and specific mode of action / Crosses the blood-brain barrier / Co-evolution with our organism (low risk of adverse side effect).

YOUR INNOVATIVE SOLUTION:

AXENIS business model is based on the following three ideas :

-Central focus on humanized mouse models and their applications;

-Feed the flow of in-licensed new models and innovations in order to generate the richest possible catalogue of humanized models and pre-clinical studies and accumulate latest models and

related knowledge

-Offer pre-clinical studies to the biopharma industry.

WHICH PROBLEM ARE YOU SOLVING?

-Human immuno-profiling for drug discovery and validation;

-Searching for and validating predictive biomarkers of disease progression or resolution (infection, autoimmunity, tumor control…);development/Validation of vaccine, biologicals, small molecules, adjuvants and mAb treatments;

TARGET PARTNERS:

Partners/Licensing of immunodeficient mice :

Ø  PDX models/Sell

Ø  US/Asia/India/Europa

Ø  Co-development of new combine models (Liver/Tumor/Muscle..)

KEY VALUE PROPOSITION:

It will specialize in bringing the newest validated models to its clients and exploiting these models through in-house experimental studies. The vision of the founders is to make AXENIS a world-wide leading service company in humanized models.

B Cell Design promotes a new approach of mucosal immunotherapies. The innovation is based on a technology platform to generate a large number of drug and vaccine candidates in infectious diseases and oncology.

The preferential tropism of class A isotype for mucosal compartments is the key in treatment of infectious diseases and mucosal cancers (gut, lung) strategies.  Its high resistance (under its secretory form) through the entire digestive tracts, allow an oral administration of anti-cancer immunotherapy. B CELL DESIGN develops a new concept of therapeutic IgA and secretory IgA for anti-colorectal cancer therapy and medical imaging of early-stage metastasis. To target AIDS, B Cell Design develops an alternative vaccine approach for a mucosal induction of a neutralizing response, at the gate of entrance of the virus.

Based on an innovative platform of humanized transgenic mice models, B CELL DESIGN offers a complete panel of specific monoclonal antibodies, hIgG1, hIgA1, hIgA2, SIgA1, hIgM and hIgE. The main issue in the diagnostic industry is to solve the problem of supply in specific human sera, as positive controls and calibrators for their diagnostic kits. Plus, for some diseases, patients developed a combined immune response, requiring testing various isotypes. B CELL DESIGN offers secure solutions to overcome supplying restraints. Working with monoclonal antibodies offers a perfect reproducibility of antibodies affinity, allows keeping quality track of all components of the kit, and ensures a complete safety for users because of a non-human cellular manufacturing system.

OBJECTIVES :

B CELL DESIGN is seeking for partners to pursue the development of our drug candidates and to  initiate new projects based on our technological platform.

As a part of our advanced concept and system combining mobile hardware with sensor, smarts of software engines capabilities and personalized dashboard; our exclusive & patented BIA measurement & analysis offers a direct valuation of body composition, hydration and nutrition status at one glance.

Our unique 

Health/weight management/Sport/Seniors/

Connected Device & cloud based engine & storage technology/ The only one in this range of product to deliver instantly full body composition analysis/ Accurate & reliable / Highly personalizable and flexible

Bertin Pharma recently integrates one of the most outstanding GMP facilities in Europe specifically dedicated to the Pharmaceutical development of OTC. A large panel of original Drug Delivery Systems particularly suitable to fit the OTC needs with optimized sensorial attributes are available. Among them Dualtab

DUALTAB

Ethics (NCEs & Biologics), OTC, Generic plus 

Quick local symptoms relief Dual action quick and long lasting Product design makes dual action visible for patients Robust manufacturing process and low industrial cost price